Published in J Virol on February 01, 1998
TMC1 and TMC2 are components of the mechanotransduction channel in hair cells of the mammalian inner ear. Neuron (2013) 2.54
Mechanotransduction in mouse inner ear hair cells requires transmembrane channel-like genes. J Clin Invest (2011) 2.17
Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest (2010) 2.13
Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A (1999) 1.46
Viral and nonviral delivery systems for gene delivery. Adv Biomed Res (2012) 1.42
Role for the adenovirus IVa2 protein in packaging of viral DNA. J Virol (2001) 1.28
Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther (2009) 1.27
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res (2003) 1.23
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res (2009) 1.20
Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression. J Virol (2000) 1.18
Dominant-negative inhibition of M-like potassium conductances in hair cells of the mouse inner ear. J Neurosci (2007) 1.16
Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol (1999) 1.15
Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications. J Virol (2001) 1.07
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine (2009) 1.07
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther (2009) 1.05
A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol Lett (2008) 1.02
Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther (2010) 1.00
Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci U S A (1999) 0.98
Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets (2007) 0.98
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther (2012) 0.97
TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses. J Innate Immun (2009) 0.95
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology (2008) 0.94
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res (2010) 0.94
An in vitro model system to study gene therapy in the human inner ear. Gene Ther (2007) 0.94
Neurotrophin gene therapy for sustained neural preservation after deafness. PLoS One (2012) 0.93
Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm. Front Immunol (2011) 0.90
beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2. Virus Res (2009) 0.89
Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine (2011) 0.88
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother (2013) 0.88
CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies. Gene Ther (2009) 0.88
An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther (2011) 0.87
Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses (2010) 0.87
Rapid construction of adenoviral vectors by lambda phage genetics. J Virol (2002) 0.85
Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. J Innate Immun (2010) 0.85
A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. J Virol (1999) 0.85
An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors. J Virol (2005) 0.85
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res (2009) 0.82
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther (2015) 0.82
The function and molecular identity of inward rectifier channels in vestibular hair cells of the mouse inner ear. J Neurophysiol (2012) 0.82
Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine. Vaccine (2011) 0.82
Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. Vaccine (2012) 0.81
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother (2015) 0.80
Virally mediated gene manipulation in the adult CNS. Front Mol Neurosci (2011) 0.79
Gene delivery with viral vectors for cerebrovascular diseases. Front Biosci (Elite Ed) (2013) 0.78
The promise and potential hazards of adenovirus gene therapy. Gut (2001) 0.78
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget (2015) 0.77
In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. Brain Res Mol Brain Res (2005) 0.76
Comparison of osteogenic potentials of human rat BMP4 and BMP6 gene therapy using [E1-] and [E1-,E2b-] adenoviral vectors. Int J Med Sci (2006) 0.75
Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition. J Cancer (2017) 0.75
Combinatorial targeting of 2 different steps in adenoviral DNA replication by herpes simplex virus thymidine kinase and artificial microRNA expression for the inhibition of virus multiplication in the presence of ganciclovir. BMC Biotechnol (2013) 0.75
Generation of cell lines to complement adenovirus vectors using recombination-mediated cassette exchange. BMC Biotechnol (2010) 0.75
Stimulation of innate immunity by in vivo cyclic di-GMP synthesis using adenovirus. Clin Vaccine Immunol (2014) 0.75
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. Oncoimmunology (2017) 0.75
Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell (1981) 9.38
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
Construction of adenovirus vectors through Cre-lox recombination. J Virol (1997) 6.72
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol (1996) 6.43
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol (1995) 5.67
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol (1996) 4.97
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 4.65
Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest (1992) 4.43
Isolation of deletion and substitution mutants of adenovirus type 5. Cell (1978) 4.29
A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A (1996) 3.89
Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med (1996) 3.84
In vitro polyadenylation is stimulated by the presence of an upstream intron. Genes Dev (1990) 3.73
Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet (1994) 3.56
Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature (1993) 2.73
Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet (1992) 2.72
Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature (1993) 2.63
A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A (1996) 2.52
Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther (1993) 2.48
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 2.33
Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 2.12
Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther (1995) 2.11
Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet (1995) 2.03
Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol (1995) 1.75
Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol (1996) 1.70
Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet (1996) 1.56
Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol (1997) 1.46
Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther (1994) 1.43
In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther (1996) 1.37
Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci U S A (1997) 1.37
Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther (1997) 1.30
Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther (1996) 1.30
Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther (1995) 1.27
Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet (1993) 1.27
Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther (1996) 1.25
Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci U S A (1996) 1.23
Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther (1997) 1.20
Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol (1996) 1.08
Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther (1996) 1.05
CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Ther (1995) 1.00
Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A (1997) 0.98
Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system - first steps towards gene therapy of Alport syndrome. Gene Ther (1996) 0.97
Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. Hum Gene Ther (1996) 0.96
Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport (1994) 0.95
Detection of an adenovirus E1A-like activity in mammalian cells. Curr Top Microbiol Immunol (1984) 0.81
Diagnosis of Chlamydia trachomatis infections in men and women by testing first-void urine by ligase chain reaction. J Clin Microbiol (1994) 5.61
Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med (1998) 4.51
Class II-independent generation of CD4 memory T cells from effectors. Science (1999) 3.96
Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol (1997) 3.32
Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiency. Proc Natl Acad Sci U S A (2004) 2.97
Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature (1993) 2.63
Detection of Chlamydia trachomatis infection in urine samples from men and women by ligase chain reaction. J Clin Microbiol (1995) 2.50
Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts. Mol Cell Biol (1986) 2.47
Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet (1995) 2.40
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol (2001) 2.31
X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation (1993) 2.30
Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. Am J Hum Genet (1989) 2.12
Chemistry of single-walled carbon nanotubes. Acc Chem Res (2002) 2.10
Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil (2001) 2.06
Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. J Intern Med (2014) 2.06
Decrease in birth weight in relation to maternal bone-lead burden. Pediatrics (1997) 2.00
The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci U S A (1993) 1.97
Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the Normative Aging Study. Am J Epidemiol (2001) 1.97
Carrier detection and prenatal diagnosis in Duchenne and Becker muscular dystrophy families, using dinucleotide repeat polymorphisms. Am J Hum Genet (1991) 1.93
Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol (2000) 1.92
Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology (1989) 1.88
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone (2004) 1.84
Natural trans-splicing in carnitine octanoyltransferase pre-mRNAs in rat liver. Proc Natl Acad Sci U S A (1998) 1.83
Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol (1996) 1.79
Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A (1994) 1.78
The effectiveness of housing policies in reducing children's lead exposure. Am J Public Health (2001) 1.70
Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet (1994) 1.70
K x-ray fluorescence measurements of bone lead concentration: the analysis of low-level data. Phys Med Biol (1995) 1.70
Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet (1996) 1.69
Genotoxicity of chromium compounds. A review. Mutat Res (1990) 1.68
Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem (1995) 1.67
Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. Kidney Int (2007) 1.66
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat (2009) 1.63
Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther (2002) 1.62
Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health (1994) 1.60
Plexin-B semaphorin receptors interact directly with active Rac and regulate the actin cytoskeleton by activating Rho. Curr Biol (2001) 1.59
Regulation of creatine kinase induction in differentiating mouse myoblasts. Mol Cell Biol (1985) 1.59
The localization of the brain-specific inorganic phosphate transporter suggests a specific presynaptic role in glutamatergic transmission. J Neurosci (1998) 1.58
A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. JAMA (1996) 1.57
Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet (1996) 1.56
Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med (1996) 1.56
Improvements in the calibration of 109Cd K x-ray fluorescence systems for measuring bone lead in vivo. Phys Med Biol (1994) 1.54
Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart (2006) 1.53
Low-level lead exposure and renal function in the Normative Aging Study. Am J Epidemiol (1994) 1.51
Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol Teratol (1998) 1.50
Dietary and environmental determinants of blood and bone lead levels in lactating postpartum women living in Mexico City. Environ Health Perspect (1996) 1.48
The mdx-amplification-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele. Muscle Nerve (1996) 1.46
Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A (1999) 1.46
Correlates of fitness for duty in hazardous materials firefighters. Am J Ind Med (1999) 1.44
New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat Genet (1993) 1.42
Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med (1998) 1.38
Fitness for duty evaluations in hazardous materials firefighters. J Occup Environ Med (1998) 1.38
A polymorphism in the delta-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Perspect (1995) 1.37
Fragmented condensate ground state of trapped weakly interacting bosons in two dimensions. Phys Rev Lett (2001) 1.36
Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther (2000) 1.36
IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy (2008) 1.36
Arsenic in drinking water and incidence of urinary cancers. Epidemiology (1997) 1.35
Automated bone lead analysis by K-x-ray fluorescence for the clinical environment. Basic Life Sci (1990) 1.34
MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ (2011) 1.33
Age and secular trends in bone lead levels in middle-aged and elderly men: three-year longitudinal follow-up in the Normative Aging Study. Am J Epidemiol (1997) 1.33
mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet (1998) 1.32
Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum Mol Genet (1994) 1.32
Lead and hypertension in a sample of middle-aged women. Am J Public Health (1999) 1.32
Lead toxicity in older adults. J Am Geriatr Soc (2000) 1.31
Reactive airways dysfunction after exposure to teargas. Lancet (1992) 1.30
Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology (2004) 1.28
Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy. Hum Mol Genet (2000) 1.27
Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release. J Physiol (2006) 1.27
FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation (1997) 1.26
Identification of alpha-syntrophin binding to syntrophin triplet, dystrophin, and utrophin. J Biol Chem (1995) 1.26
Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther (2004) 1.26
Contraction-induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice. Am J Physiol Cell Physiol (2000) 1.26
Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci U S A (1996) 1.23
Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. Am J Physiol (1997) 1.23
Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med (2000) 1.23
T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res (2001) 1.22
Interrelations of lead levels in bone, venous blood, and umbilical cord blood with exogenous lead exposure through maternal plasma lead in peripartum women. Environ Health Perspect (2001) 1.22
Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther (1997) 1.20
Relation of nutrition to bone lead and blood lead levels in middle-aged to elderly men. The Normative Aging Study. Am J Epidemiol (1998) 1.20
Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther (2001) 1.19
Tumor-initiating and promoting activities of di(2-ethylhexyl) phthalate in vivo and in vitro. Environ Health Perspect (1986) 1.19
Expression of recombinant dystrophin and its localization to the cell membrane. Nature (1991) 1.19
Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. Nucleic Acids Res (1992) 1.19
Electrocardiographic conduction disturbances in association with low-level lead exposure (the Normative Aging Study). Am J Cardiol (1998) 1.19
Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Hum Mol Genet (2000) 1.18
Interactions between beta 2-syntrophin and a family of microtubule-associated serine/threonine kinases. Nat Neurosci (1999) 1.17
Relations between individual and neighborhood-based measures of socioeconomic position and bone lead concentrations among community-exposed men: the Normative Aging Study. Am J Epidemiol (1999) 1.17
Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther (2003) 1.16
Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype. J Cell Biol (1996) 1.16
Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer. Clin Transl Oncol (2012) 1.16
Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A (1998) 1.15
The influence of bone and blood lead on plasma lead levels in environmentally exposed adults. Environ Health Perspect (1998) 1.15
The mouse muscle creatine kinase cDNA and deduced amino acid sequences: comparison to evolutionarily related enzymes. J Mol Evol (1985) 1.14
Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology (2009) 1.14
Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. Hum Gene Ther (2001) 1.14